A4250 (odevixibat)

DRUG2 trials

Sponsors

Albireo, Albireo, an Ipsen Company

Conditions

PFIC1PFIC2Progressive Familial Intrahepatic Cholestasis

Phase 3

This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2

CompletedNCT03566238

AlbireoPFIC1, PFIC2

Start: 2018-05-16End: 2020-07-28Updated: 2025-11-28

Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC

CompletedNCT03659916

Albireo, an Ipsen CompanyProgressive Familial Intrahepatic Cholestasis

Start: 2018-09-28End: 2025-12-02Updated: 2026-09-03

Related Papers

OC8 Long-term efficacy and safety of odevixibat in patients with progressive familial intrahepatic cholestasis: results with ≥96 weeks of treatment

Abstracts2023-07-01

O21 Long-term efficacy and safety of odevixibat in patients with progressive familial intrahepatic cholestasis: results with ≥96 weeks of treatment

Oral Presentations2023-06-01

Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis.

2023-04-2917 citations

Validation of the PRUCISION Instruments in Pediatric Patients with Progressive Familial Intrahepatic Cholestasis.

2022-09-069 citations

Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial.

2022-07-01105 citations